Is CNC a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Centene Corporation (CNC) rests on Medicaid scale and margin recovery: Centene is the largest Medicaid managed-care organization in the US, with about 12.5 million members across roughly 30 states. Revenue (2025) is ~$194.8B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy are live concerns. Whether CNC is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Centene Corporation is a St. Louis-based managed-care organization that administers government-sponsored and subsidized health insurance. It is the largest Medicaid managed-care company in the country (roughly 12.5 million members across about 30 states), the top carrier on the Affordable Care Act Marketplace (around 5.5 million members), and a meaningful Medicare player with about 1.0 million Medicare Advantage members plus roughly 8.1 million prescription-drug-plan members. The company reported total revenue of about $194.8 billion in 2025, and the vast majority of that flows from Medicaid, Marketplace (commercial), and Medicare premiums, making Centene highly exposed to federal and state healthcare policy, reimbursement rates, and medical cost trends. The investment picture is defined by a sharp reset. In mid-2025 Centene withdrew its full-year guidance after an independent actuarial review found its ACA Marketplace risk-adjustment and morbidity assumptions were too optimistic, and the stock fell about 40% in a single session, hitting multi-year lows. Since then, the story has been about stabilization: Q1 2026 came in ahead of expectations (adjusted EPS of roughly $3.37 on about $49.9 billion of revenue) and management raised full-year 2026 guidance to roughly $187.5 to $191.5 billion of revenue with adjusted EPS expected above $3.40. The stock trades near the low $60s, a lower multiple than higher-margin peers, reflecting both the depressed earnings base and ongoing uncertainty around Medicaid funding and cost trends.
What's the case for buying CNC?
1. Medicaid scale and margin recovery
Centene is the largest Medicaid managed-care organization in the US, with about 12.5 million members across roughly 30 states. After a step-up in medical cost trend in behavioral health, home health, and high-cost drugs pressured margins, management has focused on repricing contracts with states and improving the Medicaid health-benefits ratio. Q1 2026 showed the benefits ratio improving, which is the core signal investors watch.
2. Marketplace leadership and repricing
Centene is the number-one carrier on the ACA Health Insurance Marketplace, with roughly 5.5 million members. The 2025 shock came largely from Marketplace morbidity and risk-adjustment coming in worse than assumed. The 2026 setup depends on whether repriced plans and updated risk assumptions restore profitability, even as ACA enrollment and enhanced subsidies remain policy-dependent.
3. Medicare and diversification
Centene runs a Medicare Advantage book of about 1.0 million members with a high concentration of Dual Eligible Special Needs Plan enrollees, plus a large standalone prescription-drug-plan membership. Diversification across Medicaid, Marketplace, and Medicare gives Centene multiple government-program revenue streams, though each carries its own reimbursement and utilization risks.
4. Capital returns and deleveraging
The company reported strong cash flow and reduced debt by about $1.0 billion in Q1 2026, and it has historically used buybacks to return capital. Balance-sheet cleanup and steady free cash flow are part of the rebuild-credibility narrative following the guidance withdrawal.
What are the risks to CNC?
Centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy are live concerns. Medicaid is the single largest source of revenue, and federal legislation enacted in 2025 is projected to cut a large amount of Medicaid funding over the coming years, which could reduce enrollment and pressure rates. Medical cost trends in behavioral health, home health, and high-cost drugs have run hotter than expected, and results are sensitive to state rate negotiations, redeterminations, and ACA subsidy policy. The stock is more volatile than the broader market, and the earnings base is depressed relative to prior peaks.
How is CNC valued? (as of July 2026)
Snapshot for CNC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (2025): ~$194.8B
- 2026 revenue guidance: ~$187.5B to $191.5B
- Q1 2026 adjusted EPS: ~$3.37
- 2026 adjusted EPS guidance: ~>$3.40
- Share price (mid-July 2026): ~$64
- Market cap: ~$31B
Centene trades on a low earnings multiple relative to higher-margin managed-care peers, reflecting a depressed post-2025 earnings base and elevated uncertainty. Revenue is enormous (near $195 billion) but health insurance is a thin-margin business, so small changes in the health-benefits ratio move earnings sharply. The 2026 consensus EPS sits near the mid-$3 range.
How do you decide if CNC is a buy?
Rather than asking whether CNC is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CNC indirectly through an index or sector ETF before adding more.
For the full picture, see the CNC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CNC against your real portfolio and see your actual exposure before deciding.
The bottom line on CNC
The bottom line: Centene Corporation's story right now is Medicaid scale and margin recovery, with revenue (2025) at ~$194.8B. If you believe that narrative continues, the call is about sizing CNC sensibly and checking overlap with what you own; if you doubt it (the risk: centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy are live concerns.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around CNC with Walnut
Use Centene Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is CNC a good stock to buy right now?
+
The case for Centene Corporation right now is Medicaid scale and margin recovery, with revenue (2025) at ~$194.8B. If you believe that thesis holds, CNC is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy are live concerns. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Centene Corporation do?
+
Centene Corporation is a St.
What are the main risks of CNC?
+
Centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy are live concerns. Medicaid is the single largest source of revenue, and federal legislation enacted in 2025 is projected to cut a large amount of Medicaid funding over the coming years, which could reduce enrollment and pressure rates. Medical cost trends in behavioral health, home health, and high-cost drugs have run hotter than expected, and results are sensitive to state rate negotiations, redeterminations, and ACA subsidy policy. The stock is more volatile than the broader market, and the earnings base is depressed relative to prior peaks.
What does Centene (CNC) do?
+
Centene is a managed-care organization that administers government-sponsored and subsidized health insurance. It is the largest Medicaid managed-care company in the US, the top carrier on the ACA Marketplace, and also runs Medicare Advantage and prescription-drug plans.
Why did Centene stock drop so much in 2025?
+
In mid-2025 Centene withdrew its full-year guidance after an independent actuarial review found its ACA Marketplace morbidity and risk-adjustment assumptions were too optimistic. The stock fell roughly 40% in a single session and hit multi-year lows, and Wall Street issued downgrades.
How big is Centene's revenue?
+
Centene reported total revenue of about $194.8 billion in 2025, up roughly 19% year over year. For 2026 the company has guided to revenue of roughly $187.5 billion to $191.5 billion. Health insurance is a thin-margin business, so profits are far smaller than that top line.
What are Centene's main business segments?
+
Centene operates in Medicaid (about 12.5 million members across roughly 30 states), Marketplace or commercial (about 5.5 million members), and Medicare (about 1.0 million Medicare Advantage members plus a large standalone prescription-drug-plan book).
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CNC; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.